tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Oberholzer J et al. Daclizumab as escape therapy for late acute kidney rejection in the presence of FK506 nephrotoxicity. 2000 Transpl. Int. pmid:10836657
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Moffatt SD and Metcalfe SM Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. 2000 Transplantation pmid:10836388
Chen H et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. 2000 Transplantation pmid:10836361
Gallagher H et al. Post-transplantation lymphoproliferative disorder: an unusual presentation in a patient receiving tacrolimus. 2000 Nephrol. Dial. Transplant. pmid:10831670
Filler G et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. 2000 Nephrol. Dial. Transplant. pmid:10831643
Rerolle JP et al. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. 2000 Clin Transplant pmid:10831087
Jindal RM and Dubernard JM Towards a specific immunosuppression for pancreas and islet grafts. 2000 Clin Transplant pmid:10831083
Blaheta RA et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. 2000 Transplantation pmid:10830246
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Eckhoff DE et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. 2000 Transplantation pmid:10830224
Otley CC and Pittelkow MR Skin cancer in liver transplant recipients. 2000 Liver Transpl. pmid:10827224
Bang H et al. Prolyl isomerases in a minimal cell. Catalysis of protein folding by trigger factor from Mycoplasma genitalium. 2000 Eur. J. Biochem. pmid:10824113
Ortega-Pérez I and Redondo JM [The NFAT transcription factor family as immunosuppression target]. 2000 Nefrologia pmid:10822734
Wang JJ et al. Dimerization-dependent block of the proapoptotic effect of p75(NTR). 2000 J. Neurosci. Res. pmid:10820429
Küsters E et al. Purification of an ascomycin derivative with simulated moving bed chromatography. A case study. 2000 J Chromatogr A pmid:10817355
Przepiorka D et al. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. 2000 Biol. Blood Marrow Transplant. pmid:10816027
Levy GA Neoral use in the liver transplant recipient. 2000 Transplant. Proc. pmid:10814745
McLaughlin GE et al. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. 2000 Transplant. Proc. pmid:10812158
Soran A et al. Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. 2000 Transplant. Proc. pmid:10812157
Taber DJ et al. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. 2000 Transplant. Proc. pmid:10812156
White SA et al. Randomized trial comparing neoral and tacrolimus immunousuppression for recipients of renal transplants procured from different donor groups. 2000 Transplant. Proc. pmid:10812132
Glanemann M et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. 2000 Transplant. Proc. pmid:10812095
Chen XJ et al. Positive and negative control of multidrug resistance by the Sit4 protein phosphatase in Kluyveromyces lactis. 2000 J. Biol. Chem. pmid:10809730
Riley L et al. Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. 2000 Bone Marrow Transplant. pmid:10808214
Pirsch J et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. 2000 J Clin Pharmacol pmid:10806606
Biggar SR and Crabtree GR Chemically regulated transcription factors reveal the persistence of repressor-resistant transcription after disrupting activator function. 2000 J. Biol. Chem. pmid:10801867
Adachi S et al. Successive expression and activation of NFAT family members during thymocyte differentiation. 2000 J. Biol. Chem. pmid:10799559
Moffatt SD et al. STAT 6 up-regulation by FK506 in the presence of interleukin-4. 2000 Transplantation pmid:10798785
Borger P et al. Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. 2000 Transplantation pmid:10798763
Qi S et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. 2000 Transplantation pmid:10798741
Lu YM et al. Calcineurin-mediated LTD of GABAergic inhibition underlies the increased excitability of CA1 neurons associated with LTP. 2000 Neuron pmid:10798404
Gaweco AS et al. Intragraft localization of activated nuclear factor kappaB in recurrent hepatitis C virus disease following liver transplantation. 2000 Hepatology pmid:10796896
Kiani A et al. Manipulating immune responses with immunosuppressive agents that target NFAT. 2000 Immunity pmid:10795734
Yoshizawa K et al. Time-specific occurrence of alopecia in neonatal C57BL mice treated with N-methyl-N-nitrosourea and the therapeutic efficacy of tacrolimus hydrate. 2000 Pathol. Int. pmid:10792780
Ramsay HM and Harden PN Cyclosporin-induced flushing in a renal transplant recipient resolving after substitution with tacrolimus. 2000 Br. J. Dermatol. pmid:10792253
Neckermann G et al. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. 2000 Br. J. Dermatol. pmid:10792216
Katayama Y et al. [Studies on brain pyruvate dehydrogenase (PDH) activity and energy metabolites during ischemia and reperfusion]. 1999 Rinsho Shinkeigaku pmid:10791103
Kataoka T and Nagai K Involvement of FK506-sensitive and insensitive granule exocytosis pathways in perforin-dependent target cell lysis mediated by a CD8+ CTL clone. 2000 Immunol. Lett. pmid:10789681
Gonin JM Maintenance immunosuppression: new agents and persistent dilemmas. 2000 Adv Ren Replace Ther pmid:10782729
Vestergaard C et al. The NC/Nga mouse: a model for atopic dermatitis. 2000 Mol Med Today pmid:10782068
Chini EN and Walker H FK506 (tacrolimus) increases halothane-induced Ca2+ release from skeletal muscle sarcoplasmic reticulum. 2000 Anesthesiology pmid:10781282
Peters D et al. Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. 2000 Blood pmid:10779414
Attur MG et al. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. 2000 Inflamm. Res. pmid:10778917
Yamani MH et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. 2000 J. Heart Lung Transplant. pmid:10775813
Kraiss LW et al. Fluid flow activates a regulator of translation, p70/p85 S6 kinase, in human endothelial cells. 2000 Am. J. Physiol. Heart Circ. Physiol. pmid:10775131
pmid:10773614
Outeda Macías M et al. Tacrolimus-itraconazole interaction in a kidney transplant patient. 2000 Ann Pharmacother pmid:10772445
Fernández-Miranda C et al. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. 2000 Clin Transplant pmid:10770414
Klein BC et al. Influence of mycophenolic acid and FK-506 on human platelet activation in vitro. 2000 Kidney Blood Press. Res. pmid:10765114